Cohu CEO Luis Muller Sells Shares for $3.3 Million

Cohu CEO Luis A. Muller sold 55,794 shares at a weighted-average $60.00 per share, realizing approximately $3.3 million under a Rule 10b5-1 plan adopted May 28, 2026. The sale represented 6% of his pre-sale direct stake, leaving him with 871,825 shares valued at approximately $52.9 million. Cohu shares had risen 169% over the prior 12 months; meanwhile, TTM revenue grew 33% year over year and operating loss narrowed to $36 million from $70 million, although TTM net income remained negative at $38.8 million.

Analysis

The planned sale is not, by itself, an information event: the pre-established program and modest percentage of direct ownership sharply limit its signaling value. The more relevant market implication is that COHU now has a concentrated valuation/setup risk after a rapid rerating: at roughly 44x forward earnings despite still-loss-making trailing operations, the equity requires continued order recovery and operating leverage to validate its multiple. A routine Form 4 is therefore unlikely to support a durable incremental bid.

Over the next 1-3 months, the key catalyst is evidence that semiconductor test utilization is converting into higher-margin system shipments rather than service/replacement demand. Cohu's relatively smaller scale versus Teradyne (TER) and Advantest (6857 JP) makes quarterly customer concentration, China exposure, and booking volatility disproportionately important; a single pushed program can materially alter earnings expectations. If revenue growth decelerates before profitability reaches a credible inflection, the stock can de-rate quickly because the valuation embeds a clean cycle recovery.

Contrarian view: the market may be treating all test-equipment exposure as AI-adjacent, while COHU's payoff is more tied to broad analog, automotive, industrial and outsourced semiconductor assembly/test recovery. That creates upside if these lagging end-markets inflect together, but it also means NVDA-led AI strength is an imperfect read-through. The thesis is falsified by weak bookings/backlog conversion, gross-margin deterioration, or a reduction in the timeline to sustained positive operating income at the next earnings update.

Key Decisions for Investors

• No trade on the insider filing alone; treat it as non-actionable absent additional discretionary insider sales, a plan amendment, or management guidance changes.
• For existing COHU longs, tighten risk over the next earnings print: reduce if management cannot demonstrate sequential bookings growth and a credible path to positive operating income within the following 2-3 quarters. A forward-multiple compression is the primary downside, not the $3.3M sale.
• Initiate a watchlist pair, long COHU / short TER only after independently confirmed broad-based test-equipment bookings acceleration. COHU offers higher operating leverage in an upcycle, while TER provides a more mature benchmark; invalidate if COHU's gross-margin trajectory lags TER's by more than 200 bps.
• For bearish tactical exposure, wait for a failed post-earnings rally or guidance miss rather than shorting into momentum. A put structure dated 3-6 months after the next earnings release is preferable to outright short exposure, with the catalyst being a bookings or margin disappointment.